Alzheimer's Therapeutics Program Coordinator – Neurology

Partner's Healthcare; Boston (MA); Hybrid; USD 27,000 - 39,000; Full time

Benefits offered by this job

Discounted MBTA pass

Employee perks

Job summary

Mass General Brigham’s Brigham and Women's Hospital Neurology Alzheimer’s Therapeutics Program is seeking a Program Coordinator. The role supports patient assessments, treatment coordination, data collection, and research activities in a hybrid work environment.

You will work with a multidisciplinary team to coordinate care, manage registries, and contribute to academic outputs while advancing disease-modifying therapies for Alzheimer's disease.

Qualifications

• High school diploma or equivalent required.
• Associate's degree in related field preferred.
• Administrative or program support experience required.
• Strong written and verbal communication with patients and teams.
• Excellent organizational and time management.

Responsibilities

• Coordinate patient assessments, treatment appointments, and follow-up visits.
• Manage complex treatment schedules for infusions, imaging, and evaluations.
• Review procedural checklists and determine patient eligibility.
• Serve as main contact for patients and care partners.
• Collaborate with physicians, clinicians, nurses, and researchers.
• Assist with data collection for registries and research.
• Maintain program databases and generate reports.
• Support daily program operations and financial processes.

Skills

Communication

Organizational skills

Interpersonal skills

Problem solving

Independent work

Education

High school diploma

Associate's degree preferred

Tools

REDCap

Job description

Mass General Brigham’s Brigham and Women's Hospital Neurology Alzheimer’s Therapeutics Program is seeking a Program Coordinator. The role supports patient assessments, treatment coordination, data collection, and research activities in a hybrid work environment.

You will work with a multidisciplinary team to coordinate care, manage registries, and contribute to academic outputs while advancing disease-modifying therapies for Alzheimer's disease.